ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Achillion Shares Slide On Results From Hepatitis C Study

DOW JONES NEWSWIRES Achillion Pharmaceuticals Inc.'s (ACHN) shares declined Monday as Phase II study data for its lead hepatitis C treatment was deemed disappointing in light of the recent success of peers. Bristol-Myers Squibb Co. (BMY), Gilead Sciences Inc. (GILD) and others, including Abbott Laboratories (ABT), are racing to bring an all-oral hepatitis C regimen to market, hoping to tap what is expected to be a multibillion-dollar market for such a therapy. Gilead shares surged last week as it appeared to be leading the race: it hopes to bring a GS-7977-based therapy to market late next year or in 2014. Achillion shares were down 12% at $7.25 in recent trading, pushing their decline for the past three months to 21%. Over the weekend, Achillion presented final results of a 12-week study of its ACH-1625 treatment in combination with standard-of-care treatment at a European Association for the Study of the Liver conference in Barcelona, along with plans to combine a study of the oral drug candidate with another treatment later this year. The company on Saturday had reported that in the second segment of its Phase 2a trial of ACH-1625, 94% to 100% of patients achieved a complete early virologic response after 12 weeks of the experimental treatment in combination with pegylated interferon alfa-2a and ribavirin. The company also reported the combined treatments were safe and well tolerated and produced high viral response rates. J.P. Morgan Chase & Co. (JPM) said in a research note the data Achillion presented on Saturday "raises eyebrows" as it downgraded the stock to market perform from market outperform. "Overall, the data were confusing and raised questions regarding the interim safety and efficacy analysis, particularly regarding the compounds ability to clear the virus relative to other competitive agents, liver elevations, and gastrointestinal symptoms," the analysts said. "As such, we are waiting on the sidelines until we get a better handle on the breadth of the therapeutic window." Achillion on Monday aimed to clarify data regarding end-of-treatment data included in the data presented over the weekend. The company in a statement said that 58 patients were given a once-daily dose of 200 milligrams, 400 milligrams or 800 milligrams of ACH-1625 pegylated interferon and ribavirin for 12 weeks. At the time of the presentation, 22 of the patients had completed 12 weeks of ACH-1625 plus the other two drugs followed by 12 weeks of pegylated interferon and ribavirin. At the end of 24 weeks all 22 patients had undetectable levels of the virus. "We are providing these results as we recognized that some of the data was not clear" during its presentation at the conference, Achillion President and Chief Executive Michael Kishbauch said. Oppenheimer analysts said earlier Monday that based on the results, "we believe '1625 has meaningful strategic value and could play a role in an all-oral combination regimen." However, the analysts also said that despite their favorable view of 1625 and Achillion's earlier hepatitis C pipeline they believe the stock currently "reflects appropriate value for these programs." The study data was released a few days after another study found a regimen combining experimental drugs from Gilead and Bristol-Myers suppressed the hepatitis C virus in most patients four weeks after completing treatment. In a separate study, Gilead also said a combination of its drug, GS-7977, with an older drug, ribavirin, suppressed the liver-disease-causing virus in most patients four weeks after treatment. The results bolster the prospects for an all-oral regimen for hepatitis C that eliminates an injectable drug used in the current standard treatment, interferon, which can be difficult for patients to tolerate. -By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
10/19/201405:47:20MARKET SNAPSHOT: More Than 1/3 of Dow Stocks To Report This Week
09/26/201413:25:22Abbott Laboratories ABT Announces Acquisition of CFR Pharmaceuticals
07/16/201421:16:22U.S. Hot Stocks: Hot Stocks to Watch
07/14/201418:35:14MARKET SNAPSHOT: U.S. Stocks: Dow Closes Above 17,000
07/14/201418:30:00MARKET SNAPSHOT: U.S. Stocks Rise On Earnings, M&A News
07/14/201418:24:15MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000, Eyes Record Close
07/14/201418:23:23MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,000 Again As Citi Rallies
07/14/201418:23:10MARKET SNAPSHOT: U.S. Stocks: Dow Tops 17,0000 Again As Citi...
07/14/201418:21:57Abbott Flees Struggling Business to Explore New Deals -- Market...
07/14/201418:20:11MARKET SNAPSHOT: U.S. Stocks: Futures Climb; Citigroup Results...
07/13/201406:18:25MARKET SNAPSHOT: Tech, Bank Earnings To Test Economic Recovery
06/23/201418:00:13Abbott to Acquire Russian Drug Maker Veropharm
06/16/201402:30:09Abbott Laboratories Statement re Stock Retirement Program Annual...
05/19/201402:30:13Abbott Laboratories Statement re Current Report of Form 8-K
05/15/201418:00:08Third Point Adds New Stakes in American Airlines, Anheuser-Busch
04/29/201402:30:47Abbott Laboratories Statement re Current Report on Form 8-K
04/16/201413:41:44Abbott Labs Profit Falls 31%
04/16/201403:23:12Abbott Laboratories Statement re Current Reports
04/16/201403:23:12Abbott Laboratories Statement re Proxy Materials
04/13/201408:46:33MARKET SNAPSHOT: Google, Intel, IBM Outlooks To Trump Earnings...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad